Goldney, Jonathan http://orcid.org/0000-0001-8553-8296
Sargeant, Jack A. http://orcid.org/0000-0003-0395-7329
Davies, Melanie J. http://orcid.org/0000-0002-9987-9371
Funding for this research was provided by:
National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, Leicester, UK
National Institute for Health Research (NIHR) Academic Clinical Fellowship
Article History
Received: 30 May 2023
Accepted: 17 July 2023
First Online: 19 August 2023
Acknowledgements
: Mr Michael Bonar (Creative Director, Diabetes Research Centre, College of Life Sciences, University of Leicester, Leicester, UK) designed and created the figures.
: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. SAH and MJD are supported by the Leicester NHR Leicester Biomedical Research Centre. JG, NIHR Academic Clinical Fellow (ACF-2021-11-006), is funded by Health Education England (HEE)/NIHR for this research project. The views expressed in this publication are those of the authors and not necessarily those of the NIHR, NHS or the UK Department of Health and Social Care.
: JG declares no relevant relationships or activities. JAS has received funding in the form of an investigator-initiated study grant from AstraZeneca UK. MJD has acted as consultant, advisory board member and speaker for Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sanofi, an advisory board member Lexicon, Pfizer, ShouTi Pharma Inc and Medtronic and as a speaker for AstraZeneca, Napp Pharmaceuticals, Novartis and Amgen. She has received grants from AstraZeneca, Novo Nordisk, Boehringer Ingelheim, Janssen and Sanofi-Aventis and Eli Lilly.
: JG, JAS and MJD contributed to conceptualisation and design of review. JG drafted the manuscript, JAS and MJD revised it critically for important intellectual content. All authors approved the final manuscript.